AIM: Oxidative stress plays a key role in Parkinson disease (PD), and nuclear transcription factor related to NF-E2 (Nrf-2) is involved in neuroprotection against PD. The aim of the present study was to investigate a role for nuclear factor-κB (NF-κB)/Nrf-2 in the neurotherapeutic action of dimethyl fumarate (DMF) in a mouse model of PD and in vitro in SHSY-5Y cells. RESULTS: Daily oral gavage of DMF (10, 30, and 100 mg/kg) significantly reduced neuronal cell degeneration of the dopaminergic tract and behavioral impairments induced by four injections of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Moreover, treatment with DMF prevented dopamine depletion, increased tyrosine hydroxylase and dopamine transporter activities, and also reduced the number of α-synuclein-positive neurons. Furthermore, DMF treatment upregulated the Nrf-2 pathway, increased NeuN+/Nrf-2+ cell number in the striatum, induced activation of manganese superoxide dismutase and heme oxygenase-1, and regulated glutathione levels. Moreover, DMF reduced interleukin 1 levels, cyclooxygenase 2 activity, and nitrotyrosine neuronal nitrite oxide synthase expression. This treatment also modulated microglia activation, restored nerve growth factor levels, and preserved microtubule-associated protein 2 alterations. The protective effects of DMF treatment, via Nrf-2, were confirmed in in vitro studies, through inhibition of Nrf-2 by trigonelline. INNOVATION: These findings demonstrate that DMF, both in a mouse model of PD and in vitro, provides, via regulation of the NF-κB/Nrf-2 pathway, novel cytoprotective modalities that further augment the natural antioxidant response in neurodegenerative and inflammatory disease models. CONCLUSION: These results support the thesis that DMF may constitute a promising therapeutic target for the treatment of PD. Antioxid. Redox Signal. 27, 453-471.
AIM: Oxidative stress plays a key role in Parkinson disease (PD), and nuclear transcription factor related to NF-E2 (Nrf-2) is involved in neuroprotection against PD. The aim of the present study was to investigate a role for nuclear factor-κB (NF-κB)/Nrf-2 in the neurotherapeutic action of dimethyl fumarate (DMF) in a mouse model of PD and in vitro in SHSY-5Y cells. RESULTS: Daily oral gavage of DMF (10, 30, and 100 mg/kg) significantly reduced neuronal cell degeneration of the dopaminergic tract and behavioral impairments induced by four injections of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Moreover, treatment with DMF prevented dopamine depletion, increased tyrosine hydroxylase and dopamine transporter activities, and also reduced the number of α-synuclein-positive neurons. Furthermore, DMF treatment upregulated the Nrf-2 pathway, increased NeuN+/Nrf-2+ cell number in the striatum, induced activation of manganese superoxide dismutase and heme oxygenase-1, and regulated glutathione levels. Moreover, DMF reduced interleukin 1 levels, cyclooxygenase 2 activity, and nitrotyrosine neuronal nitrite oxide synthase expression. This treatment also modulated microglia activation, restored nerve growth factor levels, and preserved microtubule-associated protein 2 alterations. The protective effects of DMF treatment, via Nrf-2, were confirmed in in vitro studies, through inhibition of Nrf-2 by trigonelline. INNOVATION: These findings demonstrate that DMF, both in a mouse model of PD and in vitro, provides, via regulation of the NF-κB/Nrf-2 pathway, novel cytoprotective modalities that further augment the natural antioxidant response in neurodegenerative and inflammatory disease models. CONCLUSION: These results support the thesis that DMF may constitute a promising therapeutic target for the treatment of PD. Antioxid. Redox Signal. 27, 453-471.
Entities:
Keywords:
Parkinson's disease; central nervous system; dimethyl fumarate; neurodegeneration
Authors: Y Muramatsu; R Kurosaki; H Watanabe; M Michimata; M Matsubara; Y Imai; T Araki Journal: J Neural Transm (Vienna) Date: 2003-10 Impact factor: 3.575
Authors: Christopher Czaniecki; Tammy Ryan; Morgan G Stykel; Jennifer Drolet; Juliane Heide; Ryan Hallam; Shalandra Wood; Carla Coackley; Keith Sherriff; Craig D C Bailey; Scott D Ryan Journal: Proc Natl Acad Sci U S A Date: 2019-06-24 Impact factor: 11.205
Authors: Alana Gomes de Souza; Iardja Stéfane Lopes; Adriano José Maia Chaves Filho; Talita Matias Barbosa Cavalcante; João Victor Souza Oliveira; Michele Albuquerque Jales de Carvalho; Klistenes Alves de Lima; Paloma Marinho Jucá; Sabrina Silva Mendonça; Melina Mottin; Carolina Horta Andrade; Francisca Cléa Florenço de Sousa; Danielle S Macedo; Marta Maria de França Fonteles Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2022-06-04 Impact factor: 3.195
Authors: Ayla Hoogendoorn; Thomas D Avery; Jiahe Li; Christina Bursill; Andrew Abell; Peter M Grace Journal: Trends Pharmacol Sci Date: 2021-02-19 Impact factor: 14.819
Authors: Walter H Moos; Douglas V Faller; Ioannis P Glavas; David N Harpp; Michael H Irwin; Iphigenia Kanara; Carl A Pinkert; Whitney R Powers; Kosta Steliou; Demetrios G Vavvas; Krishna Kodukula Journal: Biores Open Access Date: 2017-12-01
Authors: Annadurai Anandhan; Nhat Nguyen; Arjun Syal; Luke A Dreher; Matthew Dodson; Donna D Zhang; Lalitha Madhavan Journal: Aging Dis Date: 2021-07-01 Impact factor: 6.745